Dyslipidaemia. Is there any new information? Dr. A.R.M. Saifuddin Ekram
|
|
- Beatrice Maxwell
- 6 years ago
- Views:
Transcription
1 Dyslipidaemia Is there any new information? Dr. A.R.M. Saifuddin Ekram PhD,FACP,FCPS(Medicine) Professor(c.c.) & Head Department of Medicine Rajshahi Medical College Rajshahi-6000
2 New features of ATP III Focus on multiple risk factors Modifications of lipid & lipoprotein classification Support for implementation
3 Focus on multiple risk factors 1. Raises persons with DM without CHD (most of whom display multiple risk factors) to the risk level of CHD risk equivalent
4 2. Uses Framingham projections of 10-year absolute CHD risk to identify certain patients with multiple(2+) risk factors for more intensive treatment.
5 3. Identifies persons with multiple metabolic risk factors (metabolic syndrome) as candidate for intensified therapeutic lifestyle changes
6 Modifications of lipid & lipoprotein classification 1. Identifies LDL cholesterol <100 mg/dl as optimal
7 2. Raises categorical low HDL cholesterol from <35 mg/dl to <40 mg/dl because the latter is a better measure of a depressed HDL
8 3. Lowers the triglyceride classification cut-points to give more attention to moderate elevations
9 Support for implementation 1. Recommends lipoprotein analysis (TC,LDL-C,HDL-C & TG ) as preferred initial test, rather than screening for total cholesterol and HDL alone
10 2. Encourages use of plant stanols /sterols and viscous (soluble) fiber as the preferred initial test, rather than screening for total cholesterol and HDL alone
11 3. Presents strategies for promoting adherence to therapeutic lifestyle changes and drug therapies
12 4. Recommends treatment beyond LDL lowering for persons with TG > 200 mg/dl.
13 Target lipid values by level of risk Target values Level of risk LDL-C level, TC:HDL Triglyceride (definition) mmol/l ratio level, mmol/l Very high * (10-year risk of CAD >30%, or history of CV disease or diabetes) <2.5 <4 <2.0 High * (10-year risk 20%-30%) <3.0 <5 <2.0 Moderate (10-year risk 10%-20%) <4.0 <6 <2.0 Low (10-year risk <10%) <5.0 <7 <3.0 *Start medication and lifestyle changes concomitantly if values are above target values. Start medication if target values are not achieved after 3 months of lifestyle modification. Start medication if target values are not achieved after 6 months of lifestyle modification.
14 New Challenges Aging Obesity (> 27 kg/m 2 ) Type 2 DM is at epidemic proportions
15 Focal points Focus on 3 CHD, hard end-point risk levels as used in ATP III Treat to LDL and TC/HDL ratio (and apo B) targets A focus on TC/HDL and apo B ensures that TG problems associated with increased CHD risk will be adequately addressed.
16 Risk Categories Risk category 10-year risk estimate of CVD LDL-C TC:HDL-C ratio apo B High 20% Diabetes Any atherosclerotic disease <2.5 < Moderate 10% - <20% <3.5 < Low < 10% <4.5 <
17 Estimate of 10-Year Risk for Men Age determines first assignment of points Total Cholesterol Age Age Age Age Age < > Nonsmoker Smoker Systolic BP If Untreated If Treated (mmhg) < HDL points are the same for males and females and are not stratified by age
18 Percent with CAD events / 5y The Greater the LDL-C Reduction, the Better the Effect on Coronary Artery Disease Risk 25 4S-P Secondary Prevention S GREACE UC Lipid-P CARE-P CARE HPS-P HPS Lipid WOS-P GREACE WOS AFCAPS AFCAPS-P Primary Prevention mg/dl mmol/l LDL-cholesterol
19 Evidence in 1º Prevention ASCOT: Patient Population Lipid Lowering Arm (LLA) Eligibility criteria SBP 160 mm Hg and/or DBP 100 mm Hg (untreated) or SBP 140 mm Hg and/or BP 90 mm Hg (treated) TC 6.5 mmol/l (250 mg/dl) and TGs 4.5 mmol/l (400 mg/dl) years of age 3+ CVD risk factors: Male >55 years of age LVH or ECG abnormality Type 2 DM PAD or CVD (CVA or TIA) or family Hx of premature CHD Microalbuminuria/proteinuria Smoking TC/HDL >6 No history of CHD Sever et al, for the ASCOT Investigators. Lancet. 2003;361:
20 ASCOT LLA: Patient Population Risk Factor Profile All patients in ASCOT have hypertension plus 3 risk factors for CHD Hypertension Age 55 years Male Microalbumin/proteinuria Smoker Family history of early coronary disease Plasma TC:HDL-C 6 Type 2 diabetes Certain ECG abnormalities LVH Previous cerebrovascular events Peripheral vascular disease risk factors on average required for inclusion Patients with risk factor (%) Sever et al, for the ASCOT Investigators. Lancet. 2003;361:
21 DBP (mm Hg) SBP (mm Hg) Blood Pressure Changes 170 Baseline 164/95 Treated 138/ Atorvastatin 10 mg Placebo Years Sever et al, for the ASCOT Investigators. Lancet. 2003;361:
22 LDL cholesterol (mmol/l) (mg/dl) Total cholesterol (mmol/l) (mg/dl) Reductions in Total and LDL Cholesterol mmol/l 1.0 mmol/l % reduction Atorvastatin 10 mg Placebo % reduction 1.2 mmol/l 1.0 mmol/l Years Sever et al, for the ASCOT Investigators. Lancet. 2003;361:
23 Cumulative Incidence (%) Primary End Point: Nonfatal MI and Fatal CHD 4 Atorvastatin 10 mg Number of events 100 Placebo Number of events % reduction 2 1 HR = 0.64 ( ) p= Years Sever et al, for the ASCOT Investigators. Lancet. 2003;361:
24 Cumulative Incidence (%) 3 2 Secondary End Point: Fatal and Nonfatal Stroke Atorvastatin 10 mg Number of events 89 Placebo Number of events % reduction 1 HR = 0.73 ( ) p= Years Sever et al, for the ASCOT Investigators. Lancet. 2003;361:
25 Percentage with CHD event Landmark Statin Trials in 1º Prevention: LDL-C Levels vs Events 10 9 S = statin treated; P = placebo treated WOSCOPS-S WOSCOPS-P AFCAPS-S ASCOT-S AFCAPS-P ASCOT-P Primary prevention Pravastatin Lovastatin Atorvastatin (90) 2.8 (110) 3.4 (130) 3.9 (150) 4.4 (170) 4.9 (190) 5.4 (210) LDL-C, mmol/l (mg/dl) 35% LDL = 36% in Death + MI in 3.3 yrs 25% LDL = 40% in Death + MI in 5.2 yrs 26% LDL = 31% in Death + MI in 4.9 yrs Sever et al, for the ASCOT Investigators. Lancet. 2003;361:
26 Clinical trials that showed significant correlation between HDL and outcomes AFCAPS/TEXCAPS (AI and B/AI ratio, pooled data) 4S (pooled data) HHS VA-HIT DAIS HATS (FER HDL )
27 HDL and Triglycerides: Fibrate Trials N Drug Follow-up LDL TG HDL Results HHS 4081 Gemfibrozil 5.4 y -10% -43% +>10% 34% fatal/nonfatal CHD (P<0.02) BIP 3090 Bezafibrate 6.2 y -6.5% -21% +18% 9.4% nonfatal events, P=0.26 VA-HIT 2531 Gemfibrozil 5.1 y 0% -31% +6% 22% fatal/ nonfatal CHD P=0.006 DAIS 418 Fenofibrate 2 y -6% -29% +6% 23% CHD* (P=NS) *Not powered for clinical events. DAIS Investigators. Lancet. 2001;357: ; Haffner. Circulation. 2000;102:2-4; Frick. N Engl J Med. 1987;317:
28 Apo B and LDL-cholesterol Sample a Sample b LDL LDL LDL apo B LDL LDL LDL apo B LDL-C 3.0 mmol/l apo B 0.8 g/l LDL LDL LDL LDL-C 3.0 mmol/l apo B 1.6 g/l NOTE: apo B level does not correlate with serum TG level
29 apo B: Utility Not affected by fasting Not invalidated in cases of high TG Helps separate higher and lower risk patients with moderate TG increases Useful for monitoring therapy (decrease in # atherogenic particles, target < 0.9 g/l) May be extremely useful in stratifying patients with METABOLIC SYNDROME
30 Obesity* Trends Among US Adults BRFSS, 1991, 1995, and *BMI 30 or ~30 lbs overweight for 5 4 person. Mokdad et al. JAMA. 1999;282:16, 2001;286:10. No Data <10% 10%-14% 15%-19% 20%
31 Metabolic Syndrome
32 Metabolic Syndrome ( Death by a 1000 Lashes to Your Arteries ) 3 of the following abnormalities: waist circumferences 102 cm (men) 88 cm (women) serum triglycerides 1.7 mmol/l serum HDL-cholesterol 1.05 mmol/l (men) 1.30 mmol/l (women) blood pressure 130 / 85 mm Hg serum glucose 6.1 mmol/l
33 Is Diabetes a CVD Equivalent? There is a trade-off between low short-term risk vs high long term risk and the value of early vs delayed risk management Focus on glucose control has yielded suboptimal impact on macro-vascular complications
34 CV Mortality (%) Diabetes Is a CHD Equivalent No prior MI Prior MI N Nondiabetic Diabetic Haffner et al. N Engl J Med. 1998;339:
35 % Reduction Effect of Tight Glucose Control vs Tight BP Control on Events: UKPDS 0-10 Stroke Any Diabetic Endpoint Diabetes- Related Death Microvascular Complications * * * Tight glucose control Tight BP control (<150/85 mm Hg) * *P<0.05 compared with tight glucose control. Sudden death, death from hyperglycemia or hypoglycemia, fatal or nonfatal MI, angina, heart failure, stroke, renal failure, amputation of 1 digit, vitreous hemorrhage, retinal photocoagulation, blindness in one eye, or cataract extraction. Death due to MI, sudden death, stroke, peripheral vascular disease, renal disease, hyperglycemia, or hypoglycemia. Bakris et al. Am J Kidney Dis. 2000;36:
36 High Lp(a) If well over I.U./L (>1,000?) treat LDL-C to < mmol/l particularly if other risk factors (BP) present or if TC/HDL >5 JAMA 1995;274:1771-4
37 A Plethora of Non-Lipid Markers of Risk 1. Vasodilatory Endothelial Dysfunction: Brachial Ultrasound Flow-Mediated Dilation. 2. Atherosclerosis Burden/End-organ Damage: Carotid IMT, # plaques (based on carotid US), IVUS, EBCT, advanced CT, MRI 3. General Inflammatory Marker: hs-c Reactive Protein 4. Markers of Inflamed Endothelium: ICAM, VCAM, e-selectin, vwf 5. Other: Homocysteine
38 Atherosclerosis Is an Inflammatory Disease LDL E-Selectin, P-Selectin L-Selectin, Integrins VCAM-1, ICAM-1 Monocyte OxLDL M-CSF MCP-1 Intima Other inflammatory triggers Libby et al. Circulation 2002;105: Macrophage Activation & Division Media Smooth Muscle Cell Migration
39 The Acute-Phase Response Pathway Proinflammatory Risk Factors Primary Pro-inflamatory Cytokines (eg, IL-1, TNF-a) ICAM-1 Selectins, HSPs, etc. Endothelium and other cells Circulation CRP SAA HSPs=heat shock proteins; SAA=serum amyloid-a. Adapted from Libby and Ridker. Circulation. 1999;100: IL-6 Messenger Cytokine Liver
40 Statins and Inflammation: CRP Additive With Lipids Ridker. Circulation. 2001;103: Relative Risk Data From NHANES Men Women
41 CRP and Metabolic Syndrome Ridker PM et al: Circulation 2003;107:
42 Recommendations for Clinical and Public Health Practice for CRP: Statement from AHA/CDC Class I : express CRP as mg/l Class II: CRP is an independent marker of risk which may help direct further evaluation and therapy in the primary prevention of CVD in patients at intermediate global risk (10-20%/10yr) unexplained and persistent values >10 mg/l should be evaluated for non-cv causes in patients with stable/acute CAD, CRP may be useful as an independent marker of prognosis for death, MI, restenosis measure CRP twice, two weeks apart (<1 = low RR, >3 = High RR)
43 B-Mode Ultrasound Skin External Internal Bifurcation Ultrasound pulse Near wall Far wall Kanters et al. Stroke. 1997;28:
44 Risk of MI (OR) Risk of Stroke (OR) Association of Carotid IMT With MI and Stroke < < N IMT (mm) N IMT (mm) Cutpoints used were the 40th, 60th, and 80th percentiles of the IMT distribution. Adjusted for age, sex, previous MI or stroke, body mass index, smoking, systolic BP, hypertension, total cholesterol, high-density lipoprotein cholesterol, and diabetes mellitus. 44 Bots et al. Circulation. 1997;96:
45 Peripheral Artery Endothelial Function Brachial Vasoreactivity Baseline Hyperemia Nitroglycerine (Ntg) 3.94 mm 4.56 mm 4.64 mm Vasodilation = 15.7% 17.8%
46 Left anterior oblique projection with cranial angulation by MSCT coronary angiography (A) and conventional coronary angiography (B) Nieman, Koen et al, The Lancet 2001; 357:
47 Whole-body 3D MRA in a 66-year old man Nieman, Koen et al, The Lancet 2001; 357:
48 New Focus Focus on 3 CHD, hard end-point risk levels as used in ATP III Treat to LDL and TC/HDL ratio (and apo B) targets A focus on TC/HDL and apo B ensures that TG problems associated with increased CHD risk should be adequately addressed
49 Thank you all.
50
Review of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationThe Metabolic Syndrome
The Metabolic Syndrome Advances in Internal Medicine David D. Waters, MD May 21, 27 UCSF Metabolic Syndrome: Definition abdominal obesity increased waist circumference atherogenic dyslipidemia low HDL-C,
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationHow to Reduce Residual Risk in Primary Prevention
How to Reduce Residual Risk in Primary Prevention Helene Glassberg, MD Assistant Professor of Medicine Section of Cardiology Hospital of the University of Pennsylvania Philadelphia, PA USA Patients with
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationCVD Risk Assessment. Michal Vrablík Charles University, Prague Czech Republic
CVD Risk Assessment Michal Vrablík Charles University, Prague Czech Republic What is Risk? A cumulative probability of an event, usually expressed as percentage e.g.: 5 CV events in 00 pts = 5% risk This
More information1. Which one of the following patients does not need to be screened for hyperlipidemia:
Questions: 1. Which one of the following patients does not need to be screened for hyperlipidemia: a) Diabetes mellitus b) Hypertension c) Family history of premature coronary disease (first degree relatives:
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More informationOptimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden
Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD
More informationMOLINA HEALTHCARE OF CALIFORNIA
MOLINA HEALTHCARE OF CALIFORNIA HIGH BLOOD CHOLESTEROL IN ADULTS GUIDELINE Molina Healthcare of California has adopted the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel
More informationAccelerated atherosclerosis begins years prior to the diagnosis of diabetes
Joslin Diabetes Forum 211: Optimizing Care for the Practicing Clinician Risk for atherosclerosis is 2 4 times greater in patients with diabetes CVD accounts for 65% of diabetic mortality >5% of patients
More informationPlacebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationPlacebo-Controlled Statin Trials
PREVENTION OF CHD WITH LIPID MANAGEMENT AND ASPIRIN: MATCHING TREATMENT TO RISK Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationPIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia
PIEDMONT ACCESS TO HEALTH SERVICES, INC. Policy Number: 01-09-021 SUBJECT: Guidelines for Screening and Management of Dyslipidemia EFFECTIVE DATE: 04/2008 REVIEWED/REVISED: 04/12/10, 03/17/2011, 4/10/2012,
More informationPREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationLessons from Recent Atherosclerosis Trials
Lessons from Recent Atherosclerosis Trials Han, Ki Hoon MD PhD Asan Medical Center Seoul, Korea Change of concept Primary vs. secondary prevention Low risk vs. High risk High Risk CHD and equivalents CHD
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationBeyond Framingham: Risk Assessment & Treatment for Primary Prevention
Beyond Framingham: Risk Assessment & Treatment for Primary Prevention Ronald M. Goldenberg, MD, FRCPC, FACE Consultant Endocrinologist, North York General Hospital Medical Co-Director, LMC Endocrinology
More informationPlacebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationHyperlipidemia: Lowering the Bar on the Lipid Limbo. Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH
Mark slides Hyperlipidemia: Lowering the Bar on the Lipid Limbo Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH Hyperlipidemia is a common problem Nearly 50% of men in the
More information4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for
+ Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics
More informationPlacebo-Controlled Statin Trials Prevention Of CVD in Women"
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationComplications of Diabetes mellitus. Dr Bill Young 16 March 2015
Complications of Diabetes mellitus Dr Bill Young 16 March 2015 Complications of diabetes Multi-organ involvement 2 The extent of diabetes complications At diagnosis as many as 50% of patients may have
More informationLandmark Clinical Trials.
Landmark Clinical Trials 1 Learning Objectives Discuss clinical trials and their role in lipid and lipoprotein treatment in cardiovascular prevention. Review the clinical trials of lipid-altering drug
More informationTreating Lipids for Prevention of CAD in Women: Matching Therapy to Risk
TREATING LIPIDS FOR PREVENTION OF CAD IN WOMEN: MATCHING THERAPY TO RISK Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationInflammation and and Heart Heart Disease in Women Inflammation and Heart Disease
Inflammation and Heart Disease in Women Inflammation and Heart Disease What is the link between een inflammation and atherosclerotic disease? What is the role of biomarkers in predicting cardiovascular
More informationThe 10 th International & 15 th National Congress on Quality Improvement in Clinical Laboratories
The 10 th International & 15 th National Congress on Quality Improvement in Clinical Laboratories Cardiac biomarkers in atherosclerosis Najma Asadi MD-APCP Ross and Colleagues in 1973: Response to Injury
More informationsurtout qui n est PAS à risque?
3*25 min et surtout qui n est PAS à risque? 2018 ESC/ESH Hypertension Guidelines 2018 ESC-ESH Guidelines for the Management of Arterial Hypertension 28 th ESH Meeting on Hypertension and Cardiovascular
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More informationAssessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients. Copyright. Not for Sale or Commercial Distribution
CLINICAL Viewpoint Assessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients Copyright Not for Sale or Commercial Distribution By Ruth McPherson, MD, PhD, FRCPC Unauthorised
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
More informationPreclinical Detection of CAD: Is it worth the effort? Michael H. Crawford, MD
Preclinical Detection of CAD: Is it worth the effort? Michael H. Crawford, MD 1 Preclinical? No symptoms No physical findings No diagnostic ECG findings No chest X-ray X findings No diagnostic events 2
More informationHow to Reduce CVD Complications in Diabetes?
How to Reduce CVD Complications in Diabetes? Chaicharn Deerochanawong M.D. Diabetes and Endocrinology Unit Department of Medicine Rajavithi Hospital, Ministry of Public Health Framingham Heart Study 30-Year
More informationCLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More informationEnvironmental. Vascular / Tissue. Metabolics
Global Risk Reduction--WINS Picking Mom and Dad-2016 Environmental Vascular / Tissue Metabolics Stop smoking-1b Physical activity-1b Weight control-1b Chelation therapy-3c Influenza vaccination-1b Blood
More informationMacrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?
Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists
More informationPharmaceutical Help to Control Cholesterol
Pharmaceutical Help to Control Cholesterol Catherine E. Cooke, PharmD, BCPS, PAHM President, PosiHealth, Inc. Clinical Associate Professor, Univ. of Maryland This program has been brought to you by PharmCon
More informationPreventing Cardiovascular Disease With Lipid Management: Matching Therapy to Risk
PREVENTING CARDIOVASCULAR DISEASE WITH LIPID MANAGEMENT : MATCHING TREATMENT TO RISK Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationJanet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode Island Cardiology Center
Primary and Secondary Prevention of Coronary Artery Disease: What is the role of non statin drugs (fenofibrates, fish oil, niacin, folate and vitamins)? Janet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode
More informationChanging lipid-lowering guidelines: whom to treat and how low to go
European Heart Journal Supplements (2005) 7 (Supplement A), A12 A19 doi:10.1093/eurheartj/sui003 Changing lipid-lowering guidelines: whom to treat and how low to go C.M. Ballantyne Section of Atherosclerosis,
More informationCVD Prevention, Who to Consider
Continuing Professional Development 3rd annual McGill CME Cruise September 20 27, 2015 CVD Prevention, Who to Consider Dr. Guy Tremblay Excellence in Health Care and Lifelong Learning Global CV risk assessment..
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationPREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN
1980 to 2000: Death rate fell from: 542.9 to 266.8 per 100K men 263.3 to 134.4 per 100K women 341,745 fewer deaths from CHD in 2000 Ford ES, NEJM, 2007 47% from CHD treatments, 44% from risk factor modification
More informationThe Clinical Debates
The Clinical Debates Speakers: Round 2: Statins for Primary Prevention of Cardiovascular Disease Matthew Cantrell, PharmD, BCPS, is a 2000 graduate of Mt. Mercy College and 2005 graduate from the University
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS: WHERE DO WE STAND WITH THE NEW PRACTICE GUIDELINES? Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant financial relationships
More informationIs there a mechanism of interaction between hypertension and dyslipidaemia?
Is there a mechanism of interaction between hypertension and dyslipidaemia? Neil R Poulter International Centre for Circulatory Health NHLI, Imperial College London Daegu, Korea April 2005 Observational
More informationTotal risk management of Cardiovascular diseases Nobuhiro Yamada
Nobuhiro Yamada The worldwide burden of cardiovascular diseases (WHO) To prevent cardiovascular diseases Beyond LDL Multiple risk factors With common molecular basis The Current Burden of CVD CVD is responsible
More informationThe TNT Trial Is It Time to Shift Our Goals in Clinical
The TNT Trial Is It Time to Shift Our Goals in Clinical Angioplasty Summit Luncheon Symposium Korea Assoc Prof David Colquhoun 29 April 2005 University of Queensland, Wesley Hospital, Brisbane, Australia
More informationUpdate On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID?
Update On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID? Karen Aspry, MD, MS, ABCL, FACC Assistant Clinical Professor of Medicine Warren Alpert Medical School of Brown
More informationLDL cholesterol and cardiovascular outcomes?
LDL cholesterol and cardiovascular outcomes? Prof Kausik Ray, BSc (hons), MBChB, FRCP, MD, MPhil (Cantab), FACC, FESC Professor of Cardiovascular Disease Prevention St Georges University of London Honorary
More informationThe Metabolic Syndrome: Is It A Valid Concept? YES
The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA
More informationInflammation: Novel Target for Cardiovascular Risk Reduction
Inflammation: Novel Target for Cardiovascular Risk Reduction Andrew Zalewski, M.D. Thomas Jefferson University, Philadelphia GlaxoSmithKline, Philadelphia Why inflammation? Population-based studies: low
More information9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?
Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial
More informationImaging Biomarkers: utilisation for the purposes of registration. EMEA-EFPIA Workshop on Biomarkers 15 December 2006
Imaging Biomarkers: utilisation for the purposes of registration EMEA-EFPIA Workshop on Biomarkers 15 December 2006 Vascular Imaging Technologies Carotid Ultrasound-IMT IVUS-PAV QCA-% stenosis 2 ICH E
More informationNorthwestern University Feinberg School of Medicine Calculating the CVD Risk Score: Which Tool for Which Patient?
Northwestern University Feinberg School of Medicine Calculating the CVD Risk Score: Which Tool for Which Patient? Donald M. Lloyd-Jones, MD, ScM, FACC, FAHA Senior Associate Dean Chair, Department of Preventive
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
PREVENTING CARDIOVASCULAR DISEASE IN WOMEN: Current Guidelines for Hypertension, Lipids and Aspirin Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationWhich CVS risk reduction strategy fits better to carotid US findings?
Which CVS risk reduction strategy fits better to carotid US findings? Dougalis A, Soulaidopoulos S, Cholongitas E, Chalevas P, Vettas Ch, Doumtsis P, Vaitsi K, Diavasti M, Mandala E, Garyfallos A 4th Department
More informationHyperlipidemia and Cardiovascular Disease. Kathmandu November 2010 Harold E. Lebovitz, MD, FACE
Hyperlipidemia and Cardiovascular Disease Kathmandu November 21 Harold E. Lebovitz, MD, FACE Diabetes and Lifetime Risk for CHD Adjusted cummula ative incidence.7.6.5 Men 67% 3%.7.6.5 Women Diabetes No
More informationNew Guidelines in Dyslipidemia Management
The Fourth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2018 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationThe Atherogenic Dyslipidemia of Diabetes Mellitus- Not just a question of LDL-C
The Atherogenic Dyslipidemia of Diabetes Mellitus- Not just a question of LDL-C Eun-Jung Rhee Department of Endocrinology and Metabolism Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine
More informationTailored Statin Treatment for Type 2 Diabetes. Han, Ki Hoon Asan Medical Center University of Ulsan
Tailored Statin Treatment for Type 2 Diabetes Han, Ki Hoon Asan Medical Center University of Ulsan 1 Cardiovascular disease ; No1. death (2001) respiratory tract infection Other NCD S HIV/AIDS deaths during
More informationROLE OF INFLAMMATION IN HYPERTENSION. Dr Barasa FA Physician Cardiologist Eldoret
ROLE OF INFLAMMATION IN HYPERTENSION Dr Barasa FA Physician Cardiologist Eldoret Outline Inflammation in CVDs the evidence Basic Science in Cardiovascular inflammation: The Main players Inflammation as
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationThere are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?
There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,
More informationLifetime clinical and economic benefits of statin-based LDL lowering in the 20-year Followup of the West of Scotland Coronary Prevention Study
Lifetime clinical and economic benefits of statin-based LDL lowering in the 20-year Followup of the West of Scotland Coronary Prevention Study Harvey White Green Lane Cardiovascular Service and Cardiovascular
More informationSerum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic
Supplementary Information The title of the manuscript Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic stroke Xin-Wei He 1, Wei-Ling Li 1, Cai Li
More informationDiabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology
Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology Disclosures In compliance with the accrediting board policies, the American Diabetes Association requires the
More informationCardiovascular Complications in Diabetes
What is all the fuss about? Cardiovascular Complications in Diabetes Dina Shrestha MD Consultant Endocrinologist Norvic International Hospital and Medical College Hospital for Advanced Medicine and Surgery
More informationPCSK9 Inhibitors and Modulators
PCSK9 Inhibitors and Modulators Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Disclosures Speaker s
More informationTuesday, October 18 3:30 p.m. 5:30 p.m. Convention Center: Rooms 315 & 316
Ambulatory Care PRN Focus Session New Developments in Hypertension and Dyslipidemia Management Activity No. 0217-0000-11-101-L01-P (Application-Based Activity) Tuesday, October 18 3:30 p.m. 5:30 p.m. Convention
More informationDisclosures. Overview 9/30/ ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults 2014 AAHP Fall Seminar Sherry Myatt, PharmD, BCPS Assistant Director of Pharmacy for
More informationASSeSSing the risk of fatal cardiovascular disease
ASSeSSing the risk of fatal cardiovascular disease «Systematic Cerebrovascular and coronary Risk Evaluation» think total vascular risk Assess the risk Set the targets Act to get to goal revised; aupril
More informationTreatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center
Treatment of Cardiovascular Risk Factors Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center Disclosures: None Objectives What do risk factors tell us What to check and when Does treatment
More informationLipid Management: A Case-Based Approach. Overview. Simple Lipid Therapy Approach. Patients have lipid disorders of:
Lipid Management: A Case-Based Approach Patrick E. McBride, M.D., M.P.H. Professor of Medicine, Cardiovascular Medicine Associate Director, Preventive Cardiology Program UW School of Medicine and Public
More informationIntroduction. Objective. Critical Questions Addressed
Introduction Objective To provide a strong evidence-based foundation for the treatment of cholesterol for the primary and secondary prevention of ASCVD in women and men Critical Questions Addressed CQ1:
More informationUpdate on Cholesterol Management: The 2013 ACC/AHA Guidelines
Update on Cholesterol Management: The 2013 ACC/AHA Guidelines Ola Akinboboye MD MPH MBA Medical Director, Queens Heart institute Rosedale. Associate Professor of Clinical Medicine, Weill Medical College
More informationMetabolic Syndrome: An overview. Kevin Niswender MD, PhD Vanderbilt University School of Medicine
Metabolic Syndrome: An overview. Kevin Niswender MD, PhD Vanderbilt University School of Medicine Setting the scene GB, 43 yo AA man followed for hypothyroidism returns on LT4 125 mcg/d and has a TSH=1.1
More informationBiomarkers in Vascular Inflammation (hscrp, Lp-PLA 2 )
Biomarkers in Vascular Inflammation (hscrp, Lp-PLA 2 ) Inflammation; Current evidence supports a central role in all phases of the atherosclerosis from lesion initiation through to progression and, ultimately,
More informationLearning Objectives. Patient Case
Joseph Saseen, Pharm.D., FASHP, FCCP, BCPS Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Learning Objectives Identify the 4 patient populations
More informationLipid Management 2013 Statin Benefit Groups
Clinical Integration Steering Committee Clinical Integration Chronic Disease Management Work Group Lipid Management 2013 Statin Benefit Groups Approved by Board Chair Signature Name (Please Print) Date
More informationThe Burden of the Diabetic Heart
The Burden of the Diabetic Heart Dr. Ghaida Kaddaha (MBBS, MRCP-UK, FRCP-london) Diabetes Unit Rashid Hospital Dubai U.A.E Risk of CVD in Diabetes Morbidity and mortality from CVD is 2-4 fold higher than
More informationTraitements associés chez l hypertendu: Statines, Aspirine
Traitements associés chez l hypertendu: Statines, Aspirine Pr Jean-Jacques Mourad CHU Avicenne, Université Paris 13, Bobigny DU HTA, Mars 2012 jean-jacques.mourad@avc.aphp.fr Global Mortality 2000: Impact
More informationClinical Recommendations: Patients with Periodontitis
The American Journal of Cardiology and Journal of Periodontology Editors' Consensus: Periodontitis and Atherosclerotic Cardiovascular Disease. Friedewald VE, Kornman KS, Beck JD, et al. J Periodontol 2009;
More informationThe Latest Generation of Clinical
The Latest Generation of Clinical Guidelines: HTN and HLD Dave Brackett Clinical Guideline Purpose Uniform approach Awareness of key details Diagnosis Treatment Monitoring Evidence based approach Inform
More informationCalculating RR, ARR, NNT
Calculating RR, ARR, NNT In a trial RR = Event rate (eg # of people with one stroke/ total people) in treatment group/event rate in the control group. ARR = Event rate in control group minus the event
More informationCopyright 2017 by Sea Courses Inc.
Diabetes and Lipids Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic, or
More informationNew Guidelines in Dyslipidemia Management
The Third IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2017 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationLipid Management: Beyond LDL
Lipid Management: Beyond LDL Lisa R. Tannock MD Division of Endocrinology and Molecular Medicine University of Kentucky Overview Discuss the concept of residual risk Review current evidence-based medicine
More informationProf. John Chapman, MD, PhD, DSc
Prof. John Chapman, MD, PhD, DSc Director of the Dyslipidemia and Atherosclerosis Research Unit of the National Institute for Health and Medical Research (INSERM) at the Pitié-Salpétrière Hospital in Paris
More informationKnow Your Number Aggregate Report Single Analysis Compared to National Averages
Know Your Number Aggregate Report Single Analysis Compared to National s Client: Study Population: 2242 Population: 3,000 Date Range: 04/20/07-08/08/07 Version of Report: V6.2 Page 2 Study Population Demographics
More informationLIST OF ABBREVIATIONS
Diabetes & Endocrinology 2005 Royal College of Physicians of Edinburgh Diabetes and lipids 1 G Marshall, 2 M Fisher 1 Research Fellow, Department of Cardiology, Glasgow Royal Infirmary, Glasgow, Scotland,
More informationCauses of death in Diabetes
Rates of CV events in Diabetes patients Respiratory4.2 Cancer 7.6 Diabetes 1.3 CV disease 17.3 Causes of death in Diabetes 250 200 150 100 50 0 per 10,000 person-years 97 151 243 Framingham 5 X increase
More information